【Objective】Ceramide has been emerging as an anti-inflammatory lipid, and nanoscale delivery system of ceramides is a potential therapeutic strategy for inflammatory diseases. In this study, we evaluated the therapeutic effect of ceramide formulation (nanoliposomal ceramides) on allergic asthma in a mouse model.
【Methods】BALB/c mice sensitized with ovalbumin (OVA) were treated with nanoliposomal ceramides or ceramide-free liposomes followed by multiple OVA challenges. The numbers of mononuclear cells, eosinophils and neutrophils infiltrated in bronchoalveolar lavage fluids were counted. Airway remodeling was evaluated by staining with PAS and Masson trichrome. Type 2 cytokines in homogenized right lungs were measured by ELISA.
【Results】Treatment with nanoliposomal ceramides suppressed OVA-induced infiltration of mononuclear cells, eosinophils and neutrophils into the lung and development of airway remodeling. However, OVA-induced production of type 2 cytokines was not changed by nanoliposomal ceramides.
【Conclusions】Nanoliposomal ceramides are suggested to have anti-asthmatic effects by suppressing the development of airway remodeling. Our study gives insight into the development of ceramide-based therapy for allergic asthma.